Show simple item record

Age-related difference in cardiac adaptation to chronic hypertension in rats, with and without nifedipine treatement

dc.contributor.authorMalhotra, Ashwanien_US
dc.contributor.authorSkipper, Bettyen_US
dc.contributor.authorRaizada, Veenaen_US
dc.contributor.authorPathak, Dorothyen_US
dc.contributor.authorNakouzi, Antonioen_US
dc.date.accessioned2006-09-11T15:56:30Z
dc.date.available2006-09-11T15:56:30Z
dc.date.issued1999-08en_US
dc.identifier.citationRaizada, Veena; Pathak, Dorothy; Skipper, Betty; Nakouzi, Antonio; Malhotra, Ashwani; (1999). "Age-related difference in cardiac adaptation to chronic hypertension in rats, with and without nifedipine treatement." Molecular and Cellular Biochemistry 198 (1-2): 109-112. <http://hdl.handle.net/2027.42/45335>en_US
dc.identifier.issn0300-8177en_US
dc.identifier.issn1573-4919en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45335
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10497884&dopt=citationen_US
dc.description.abstractThree myosin isozymes, V1 (αα MHC = Myosin Heavy Chain gene), V2 (αβ MHC) and V3 (ββ MHC) that are identified in the cardiac ventricles of most mammals have been shown to shift to a V3 predominance pattern during cardiac growth and in response to left ventricular pressure overload, and to V1 predominance following anti hypertensive treatment. This study examined whether long-term hypertension impairs the ability of the adult heart to restructure myosin isozyme proportions. Using pyrophosphate gel electrophoresis, we studied proportions of cardiac myosin isozymes (V1 and V3) in young (16 weeks) and adult (36 weeks) spontaneously hypertensive rats (SHR), and following 12 weeks of nifedipine (N) treatment in age-matched SHR rats (SHR-N). The values of V1 and V3 myosin isozymes were derived by adding half of the value of V2 to each isozyme proportion. The V3 proportion in the young SHR control (SHR-C) group (49%) was 34% higher (p < 0.05) than in the young Wistar Kyoto control (WKY-C) group (37%). However, the proportion was similarly high, though not statistically significant, in both the adult SHRC (73%) and WKY-C (71%) groups. The proportion in the young SHR-N group (29%) was 41% lower (p < 0.05) than in the young SHR-C group (49%), and the proportion in the adult SHR-N group (47%) was 34% lower (p < 0.05) than in the adult SHR-C group (73%). The ratio of left ventricular weight to body weight (LVW/BW), which determines left ventricular hypertrophy (LVH), was higher in both young and adult SHR-C (26%, p < 0.05, and 42%, p < 0.05, respectively) than in WKY-C groups. The mean LVW/BW was 27% (p lt; 0.05) greater in adult than in young SHR-C rats. The LVW/BW in both age groups of treated SHR-N was similar to that in age matched WKY-C rats. Conclusion: Our study showed that a rise in the V3 level occurs in young hypertensive rats, but no rise occurs in the V3 level in adult hypertensive rats. High blood pressure seems to contribute to the high V3 level in young hypertensive rats, but in adult hypertensive rats, high blood pressure does not accentuate the V3 rise already acquired due to the aging process. Nifedipine treatment in both young and adult hypertensive rats prevented the V3 rise due to hypertension and to the aging process. This effect of nifedipine seems to be through its antihypertensive action.en_US
dc.format.extent21373 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedical Biochemistryen_US
dc.subject.otherHypertensionen_US
dc.subject.otherMyosin Isozymeen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherCardiologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherLVHen_US
dc.subject.otherAgingen_US
dc.subject.otherNifedipineen_US
dc.subject.otherLife Sciencesen_US
dc.titleAge-related difference in cardiac adaptation to chronic hypertension in rats, with and without nifedipine treatementen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Family and Community Medicine, University of Michigan, East Lansing, Michigan; Department of Medicine, Monteflore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; Department of Medicine, New York Medical College, Valhalia, NY, USAen_US
dc.contributor.affiliationumDepartment of Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Family and Community Medicine, University of Michigan, East Lansing, Michigan; Department of Medicine, Monteflore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; Department of Medicine, New York Medical College, Valhalia, NY, USAen_US
dc.contributor.affiliationumDepartment of Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Family and Community Medicine, University of Michigan, East Lansing, Michigan; Department of Medicine, Monteflore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; Department of Medicine, New York Medical College, Valhalia, NY, USAen_US
dc.contributor.affiliationumDepartment of Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Family and Community Medicine, University of Michigan, East Lansing, Michigan; Department of Medicine, Monteflore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; Department of Medicine, New York Medical College, Valhalia, NY, USAen_US
dc.contributor.affiliationumDepartment of Medicine, University of New Mexico School of Medicine, Albuquerque, NM; Family and Community Medicine, University of Michigan, East Lansing, Michigan; Department of Medicine, Monteflore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA; Department of Medicine, New York Medical College, Valhalia, NY, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid10497884en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45335/1/11010_2004_Article_199277.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1006968011206en_US
dc.identifier.sourceMolecular and Cellular Biochemistryen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.